Cytokinetics to Present Nine MYQORZO® and Omecamtiv Mecarbil Studies at ESC Congress
Cytokinetics will deliver nine presentations at the European Society of Cardiology Heart Failure 2026 Congress in Barcelona May 9–12, showcasing MYQORZO® (aficamten) data including a late-breaking oral session and rapid-fire SEQUOIA-HCM and MAPLE-HCM analyses. An additional poster examines omecamtiv mecarbil efficacy by QRS duration in GALACTIC-HF.
1. ESC Heart Failure Congress Presentations
Cytokinetics will showcase nine distinct abstracts at the ESC Heart Failure 2026 Congress in Barcelona from May 9–12, covering both aficamten (MYQORZO®) and omecamtiv mecarbil research. Formats include a late-breaking science oral presentation, rapid-fire talks, moderated posters and ePoster sessions across clinical, safety and economic topics.
2. Late-Breaking Science and Rapid-Fire Aficamten Data
On May 11, a late-breaking oral session will present dose-dependent effects of aficamten versus metoprolol from the MAPLE-HCM study. Rapid-fire presentations will follow data on left atrial mechanics improvements from SEQUOIA-HCM and sex-based response differences to aficamten in MAPLE-HCM participants.
3. Omecamtiv Mecarbil and Poster Sessions
A dedicated session will examine how QRS duration and resynchronization status influence omecamtiv mecarbil outcomes in HFrEF patients from the GALACTIC-HF trial. Moderated posters will detail arrhythmia burden post-aficamten treatment, NYHA class economic impacts, guideline therapy outcomes and work productivity impairments in hypertrophic cardiomyopathy populations.